NCT06654011View on ClinicalTrials.gov

IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

November 1, 2026

Conditions
Cervical AdenocarcinomaGastric-type Endocervical Adenocarcinoma
Interventions
DRUG

IN10018

100 mg, orally, once daily

DRUG

Nab-paclitaxel

260 mg/m², IV infusion, Q3W

DRUG

Cadonilimab

10 mg/kg, IV infusion, Q3W

Trial Locations (2)

430000

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

441000

RECRUITING

Xiangyang Central Hospital, Xiangyang

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER